newsfilter
← Latest News
Business Wire·

bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

BIAFBIAFW
  • bioAffinity Technologies, Inc. entered a definitive agreement with an institutional investor to sell common stock or pre-funded warrants at $6.122 per share ($6.115 per pre-funded warrant) via a registered direct offering priced at-the-market.
  • The concurrent private placement involves selling warrants to purchase up to 980,072 shares at an exercise price of $6.122 per share, with pre-funded warrants exercisable at $0.007 per share.
  • All warrants will become exercisable following stockholder approval \& expire five years from that approval date.
  • The offering closing is expected on or about October 9, 2026, subject to customary conditions.
  • WallachBeth Capital, LLC acts as the sole placement agent for the transaction.
  • Gross proceeds are estimated at approximately $4 million before fees \& expenses, with net proceeds intended for working capital, supporting sales of CyPath® Lung, \& general corporate purposes.
  • The offering is conducted under a Form S-3 shelf registration statement declared effective by the SEC on November 27, 2023.
  • bioAffinity Technologies develops noninvasive healthcare solutions, including the CyPath® Lung test marketed as a Laboratory Developed Test (LDT).